Jim Simons acquired 96.8k Kalaris Therapeutics shares worth $451k. That's 0.00% of their equity portfolio (2826th largest holding). The stake costed the investor $268k, netting the investor a gain of 68% so far.
Avg closing price
Price range
Increased shares by 402.6% (+77.5k shares)
Q2 2025